This study is looking at whether adding a drug called Docetaxel to the usual treatment for prostate cancer can help stop the cancer from growing or spreading. Prostate cancer is a type of cancer that happens in a man's prostate, a small gland that makes seminal fluid. The usual treatment involves stopping male hormones (like testosterone) that help cancer grow. This is called Androgen Deprivation Therapy (ADT) and using drugs called Androgen-Receptor Pathway Inhibitors (ARPI). This trial will compare adding Docetaxel to ADT and ARPI with just using ADT and ARPI.

• This study is for men with prostate cancer that has spread to other parts of the body, who haven't responded well to hormone therapy after 6-12 months.
• Participants must have certain health conditions, like no severe heart disease or other cancers that could interfere with the study.
• The study is international, meaning it will happen in different countries, and participants will need to agree to follow study procedures and attend follow-up visits.